| Kim, Paul R |
| Recruiting | 4 | 376 | US | Regadenoson, Lexiscan | Paul Kim | Heart Transplant Failure and Rejection | 12/24 | 12/24 | | |
| Recruiting | 3 | 500 | US | Anticoagulant Therapy, Catheter-Directed Therapy | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Embolism | 01/27 | 01/28 | | |
NCT05417074: Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide |
|
|
| Not yet recruiting | 2 | 10 | US | Placebo, SLS-002, Intranasal Racemic Ketamine, Standard of care | Johns Hopkins University, Seelos Therapeutics, Inc. | Depression, Suicidal Behavior, Suicidal Ideation | 03/23 | 08/23 | | |
ELIMINATE, NCT05488340: A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli ( Trial) |
|
|
| Recruiting | 2 | 318 | US | LBP-EC01 0.1 x IV dose, 1x10^11 PFU IV dose, LBP-EC01 0.01x IV Dose, 1x10^10 PFU IV Dose, LBP-EC01 IV Infusion Dose, 1x10^12 PFU IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX | Locus Biosciences, Parexel | Urinary Tract Infections | 06/25 | 12/25 | | |
NCT03543007: Evaluating the Safety and Efficacy of GrafixPL™PRIME for the Treatment of Chronic Venous Leg Ulcers |
|
|
| Not yet recruiting | N/A | 30 | US | GrafixPL™ PRIME plus standard compression therapy, standard compression therapy alone | Georgetown University, Osiris Therapeutics | Venous Leg Ulcer, Chronic Leg Ulcer, Venous Insufficiency, Venous Stasis | 09/22 | 01/23 | | |
| Recruiting | N/A | 200 | US | Lumbar Interbody Fusion | 3Spine, MCRA | Lumbar Spine Degeneration | 05/24 | 08/26 | | |
NCT04684901: Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures |
|
|
| Enrolling by invitation | N/A | 50 | US | AlloWrap® Amniotic Membrane | AlloSource | Cervical Stenosis, Spondylolisthesis, Cervical Radiculopathy, Cervical Disc Disorder | 06/25 | 01/26 | | |
ACES-EMB, NCT06414603: A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy |
|
|
| Not yet recruiting | N/A | 250 | US | The Prospera™ Test | Natera, Inc. | Heart Transplant Failure and Rejection | 12/24 | 12/25 | | |
DEFINE-HT, NCT05309382: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation |
|
|
| Active, not recruiting | N/A | 147 | US | Prospera | Natera, Inc. | Heart Transplant | 12/24 | 12/24 | | |
NCT01420237: Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study |
|
|
| Active, not recruiting | N/A | 352 | Europe, Canada, US | Restoration ADM X3 Device | Stryker Orthopaedics | Arthroplasty, Replacement, Hip | 06/26 | 06/26 | | |
| Steinberg, John |
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care |
|
|
| Recruiting | N/A | 200 | US | Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings | ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US) | Diabetic Foot Ulcer | 12/23 | 12/23 | | |
| Attinger, Christopher |
NCT04543240: Bacterial Load for Integraâ„¢ in Operative Wounds |
|
|
| Recruiting | N/A | 54 | US | Integraâ„¢ dermal regeneration template | Georgetown University, Integra | Wounds and Injuries | 01/21 | 01/21 | | |
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care |
|
|
| Recruiting | N/A | 200 | US | Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings | ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US) | Diabetic Foot Ulcer | 12/23 | 12/23 | | |
| Evans, Karen Kim |
| Recruiting | 4 | 20000 | US | Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet | Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences | Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases | 12/26 | 12/26 | | |
| Recruiting | 2/3 | 120 | US | probenecid, Placebo | VA Office of Research and Development | Heart Failure | 05/25 | 11/25 | | |
